Cynosure, Inc.
5 Carlisle Road
Westford,
MA 01886
United States - Map
Phone: 978-256-4200
Fax: 978-256-6556
Web Site: http://www.cynosurelaser.com
| Cynosure, Inc. develops and markets aesthetic treatment systems to the dermatology, plastic surgery, and general medical markets. Its systems incorporate a range of laser and other light-based energy sources, including Alexandrite, pulse dye, Nd:Yag, and diode lasers, as well as intense pulsed light. The company offers 18 different aesthetic treatment systems, including the Apogee Elite system for hair removal; the Cynergy system for the treatment of vascular lesions; the TriActive LaserDermology system for the temporary reduction of the appearance of cellulite; the Affirm and Affirm CO2 systems for anti-aging, including treatments for wrinkles, skin texture, skin discoloration and skin tightening; the Smartlipo and Smartlipo MPX systems for LaserBodySculpting for the removal of unwanted fat; and Accolade system for the removal of benign pigmented lesions, including pigmented lesions known as Nevus of Ota and Nevus of Ito, as well as multi-colored tattoos. Cynosure sells its products through a direct sales force in North America, 4 European countries, Japan, and China, as well as through international distributors in 55 other countries. The company was founded in 1991 and is based in Westford, Massachusetts. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Michael R. Davin , 52
Chairman, Chief Exec. Officer and Pres |
$
1.10M |
$
1.60M | Mr. Timothy W. Baker , 49
Chief Financial Officer, Principal Accounting Officer, Exec. VP and Treasurer |
$
485.00K |
$
800.00K | Mr. Douglas J. Delaney , 42
Exec. VP of Sales |
$
482.00K |
$
800.00K | Mr. George Cho , 65
Sr. VP of Medical Technology & Regulatory Affairs |
N/A
| N/A | Mr. William T. Kelley ,
Sr. VP of International Sales |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.03% Nasdaq 0.00%
Profile
